| THE ROCKEFELLER UNIVERSITY Patent applications |
| Patent application number | Title | Published |
|---|
| 20120135000 | METHODS AND COMPOSITIONS FOR TREATING OCULAR DISORDERS - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis of AMD. | 05-31-2012 |
| 20120134988 | POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS - The invention provides methods of altering properties of Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region. Proteins having Fc regions having altered sialylation patterns are also provided. | 05-31-2012 |
| 20120121597 | FUSION PROTEINS FOR HIV THERAPY - Disclosed herein are fusion antibodies created to provide both an antigen-binding site that targets the CD4 receptor and an antigen-binding site that targets the HIV envelope. The fusion antibodies disclosed herein provide improved potency and breadth against HIV as compared to monospecific antibodies, and additionally provide high barrier against viral resistance. Also disclosed are pharmaceutical formulations and therapeutic methods utilizing such fusion proteins. | 05-17-2012 |
| 20120102594 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 04-26-2012 |
| 20120077265 | MicroRNA and Methods for Inhibiting Same - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 03-29-2012 |
| 20120070892 | DNA Virus MicroRNA and Methods for Inhibiting Same - The invention relates to isolated nucleic acid molecules comprising the sequence of a human cytomegalovirus microRNA. In another embodiment, the invention relates to single stranded DNA virus microRNA molecules comprising the sequence of a human cytomegalovirus microRNA. The invention also relates to the anti-DNA virus microRNA molecules. | 03-22-2012 |
| 20120034616 | Method for Modulating Epithelial Stem Cell Lineage - The present invention relates to methods of modulating epithelial stem cell lineage by regulating the expression of Lef1 or a BMP inhibitor and/or the stability of β-catenin or the expression of a Wnt; regulating the expression or activity of GATA-3; or regulating BMPR1A activity either at the level of receptor expression or at the level of pathway activation. Methods of regulating E-cadherin, GATA-3, BMPR1A and HK1-hair keratin and methods of identifying agents which modulate the epithelial stem cell lineage are further provided. Such agents are useful for inhibiting or stimulating inner root sheath development or hair follicle formation. | 02-09-2012 |
| 20120026313 | HOLOGRAPHIC MICROSCOPE - A holography attachment device for a digital imaging device. The holography attachment device including a chamber having a proximate end configured to attach to the digital imaging device. A distal end of the chamber includes a wall. Also, the chamber includes a sample holder section located between the proximate end and the distal end. The sample holder section is configured to receive a sample. The chamber is configured to attach to the digital imaging device. | 02-02-2012 |
| 20110318730 | MICROPATTERNED CO-CULTURE SYSTEMS AS INFECTIOUS DISEASE ANALYSIS PLATFORMS - Cell cultures are provided that include a population of micropatterened hepatocytes and one or more non-parenchymal cell populations, where the hepatocytes are infected with a virus or parasite and include a reporter of virus or parasite infection. Methods of making and using the cell cultures are also provided. | 12-29-2011 |
| 20110312897 | CATHEPSIN L PROTEOLYTICALLY PROCESSES HISTONE H3 DURING MOUSE EMBRYONIC STEM CELL DIFFERENTIATION - Methods and agents useful for modulating histone proteolysis, stem cell differentiation, and gene transcription and for treating cancer are disclosed. Antibodies or antigen binding fragments that selectively bind to histone-3 cleavage products and are useful for diagnosing cancer and monitoring a subject's response to cancer treatment are also disclosed. | 12-22-2011 |
| 20110271356 | HCV ENTRY FACTOR, OCCLUDIN - The human Occludin protein is identified as an essential Hepatitis C Virus (HCV) cell entry factor. Occludin is shown to render murine and other non-human cells infectable with HCV and to be required for HCV—susceptibility of human cells. Associated methods for inhibiting HCV infection, transgenic animal models for HCV pathogenesis, methods of identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin, and HCV inhibitory agents are also disclosed. Kits and cell culture compositions useful for identifying compounds or agents that prevent or mitigate interaction of HCV with Occludin are also provided. | 11-03-2011 |
| 20110263495 | METHODS AND KITS FOR TREATING DISEASE BY ADMINISTERING INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN-2 - The present invention is directed to methods of treating Type I diabetes by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods treating Type 2 diabetes comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is further directed to methods treating insulin resistance comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. The present invention is directed to methods of treating hepatic steatosis by administering a therapeutically effective amount of an Insulin-like Growth Factor-binding protein-2. The present invention is also directed to methods lowering blood glucose and serum insulin in non-diabetic subjects comprising the step of administering a therapeutically effective amount of Insulin-like Growth Factor-binding protein-2. | 10-27-2011 |
| 20110252506 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 10-13-2011 |
| 20110244523 | Modified RNA Ligase for Efficient 3` Modification of RNA - The invention provides a novel truncated mutated T4 RNA ligase 2. In addition, methods are provided for ligating pre-adenlylated donor molecules to the 3′ hydroxyl group of RNA in the absence of ATP using the ligase. | 10-06-2011 |
| 20110217718 | Methods and Kits for Distinguishing Between Specific and Non-Specific Protein Associations - The present invention is method of determining whether or not associations between a given protein and other proteins in a cell are specific. The method comprises (a) providing a first sample of the cells in which the given protein contains a tag, (b) providing a second sample of the same cells, wherein the given protein and the other proteins are metabolically labeled, and wherein neither the given protein nor the other proteins are tagged, (c) mixing and lysing the first cell sample and the second cell sample to provide a mixture of proteins, (d) binding the tag of the given protein to a substrate, (e) isolating proteins associated with the tagged given protein bound to the substrate, whereby the associated proteins comprise: (i) proteins specifically associated with the tagged given protein, (ii) proteins non-specifically associated with the tagged given protein, or (iii) a combination thereof, (f) determining whether each associated protein is unlabeled or a mixture of labeled and unlabeled proteins, wherein if the associated protein is not labeled, then that protein was specifically associated in the cell with the tagged given protein. | 09-08-2011 |
| 20110213439 | Neuromodulation Having Non-Linear Dynamics - Methods of neuromodulation in a live mammalian subject, such as a human patient. The method comprises applying electromagnetic energy to a target site in the nervous system of the subject using a signal comprising a series of pulses, wherein the inter-pulse intervals are varied using the output of a deterministic, non-linear, dynamical system comprising one or more system control parameters. In certain embodiments, the target site may be a site in the brain involved in generalized CNS (central nervous system) arousal. The dynamical system may be capable of exhibiting chaotic behavior. Also provided are apparatuses for neuromodulation and software for operating such apparatuses. | 09-01-2011 |
| 20110159599 | Voltage Sensor Domains of Voltage-Dependent Ion Channel Proteins and Uses Thereof - A composition of matter suitable for use in identifying chemical compounds that bind to voltage-dependent ion channel proteins, the composition comprising a screening protein that comprises an ion channel voltage sensor domain of the ion channel protein immobilized on a solid support. | 06-30-2011 |
| 20110150867 | POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS - The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2,6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody. | 06-23-2011 |
| 20110130328 | FLAVIVIRUS FUSION INHIBITORS - The present invention provides an isolated peptide having an amino acid sequence selected from the group consisting of SEQ ID NO:1 to SEQ ID NO:36, as well as derivatives thereof comprising various N-terminal and C-terminal chemical moieties, substituted analogs thereof, and fragments thereof. The peptides of the invention are useful for treating and preventing a Flavivirus invention. Pharmaceutical compositions comprising the peptides, and methods of treating or preventing Flavivirus infections, are also provided. | 06-02-2011 |
| 20110086053 | Glycolipids And Analogues Thereof As Antigens For NKT Cells - This invention relates to immunogenic compounds which serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 04-14-2011 |
| 20110078823 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 03-31-2011 |
| 20110076676 | Method of Purifying RNA Binding Protein-RNA Complexes - The present invention provides methods for purifying RNA molecules interacting with an RNA binding protein (RBP), and the use of such methods to analyze a gene expression profile of a cell. The invention also provides sequences of RNA molecules that mediate binding to an RBP, proteins encoded by the sequences, a method of identifying the sequences, and the use of the sequences in a screen to identify bioactive molecules. The invention also provides RNA motifs found among the sequences and compounds that bind the RNA motifs. In addition, the invention provides methods of treating diseases associated with a function of an RNA binding protein. | 03-31-2011 |
| 20110076277 | METHODS OF IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS - A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN | 03-31-2011 |
| 20110059159 | NANOSCALE BOUND BILAYERS, METHODS OF USE AND PRODUCTION - Methods for rapidly obtaining a nanoscale apolipoprotein bound phospholipid bilayer (NABB) associated with at least one membrane protein are provided. Also disclosed are methods for rapidly obtaining a NABB not associated with membrane proteins. Immunogenic compositions comprising NABBs with native conformational epitopes are also provided along with their methods of use. | 03-10-2011 |
| 20110052584 | METHOD OF ENHANCEMENT OF CYTOTOXICITY IN ANTIBODY MEDIATED IMMUNE RESPONSES - The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular, disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to FcγRIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting FcγRIIB molecule is a potent regulator of cytotoxicity in vivo. | 03-03-2011 |
| 20100316675 | GLYCOSYLTRANSFERASES FOR BIOSYNTHESIS OF OLIGOSACCHARIDES, AND GENES ENCODING THEM - The present invention is directed to nucleic acids encoding glycosyltransferases, the proteins encoded thereby, and to methods for synthesizing oligosaccharides using the glycosyltransferases of the invention. In particular, the present application is directed to identification a glycosyltransferase locus of | 12-16-2010 |
| 20100278868 | Codon-Optimized Dna Molecules Encoding the Receptor Binding Domains of Clostridium Difficile Toxins A and B, and Methods of Use Thereof - In one aspect, the invention provides a DNA molecule. The DNA molecule includes a nucleotide sequence that encodes the receptor-binding domain of | 11-04-2010 |
| 20100240133 | Compositions and Methods for Transposon Mutagenesis of Human Embryonic Stem Cells - PiggyBac transposons and transposases with enhanced transposition activity in cells are provided. Also provided are associated methods and kits for both introducing exogenous DNA inserts into the genomes of host cells as well as for the removal of the inserts from the host cell genomes. Cells obtained by use of the compositions, methods and kits are also provided. | 09-23-2010 |
| 20100233706 | METHODS TO FIX AND DETECT NUCLEIC ACIDS - In one aspect, the invention relates to a method for fixing a short nucleic acid in a biological sample. In another aspect, the invention relates to a method for detecting a target short nucleic acid in a biological sample. The method includes contacting the biological sample with an aldehyde-containing fixative, and subsequently contacting the sample with a water-soluble carbodiimide. In a further aspect, the invention relates to a kit for fixing a short nucleic acid in a biological sample. The kit includes a support substrate for holding the sample; an aldehyde-containing fixative; and a water-soluble carbodiimide. | 09-16-2010 |
| 20100222413 | Chemically Modified Oligonucleotides for Use in Modulating Micro RNA and Uses Thereof - This invention relates generally to chemically modified oligonuceotides useful for modulating expression of microRNAs and pre-microRNAs. More particularly, the invention relates to single stranded chemically modified oligonuceotides for inhibiting microRNA and pre-microRNA expression and to methods of making and using the modified oligonucleotides. Also included in the invention are compositions and methods for silencing microRNAs in the central nervous system. | 09-02-2010 |
| 20100209422 | ANTIBODIES SPECIFIC FOR THE PROTOFIBRIL FORM OF BETA-AMYLOID PROTEIN - Isolated antibodies have been characterized which show specific affinity to a repeating conformational epitope of a protofibril form of the human β-amyloid peptide as compare to low molecular weight forms of β-amyloid peptide. These isolated antibodies and related pharmaceutically effective compositions may be useful in the therapeutic and/or prophylactic treatment of Alzheimer's disease by effectively blocking the ability of the protofibril form of β-amyloid peptide to form fibril forms linked with complications associated with Alzheimer's disease. The isolated antibodies of the present invention are also useful in various diagnostic assays and associated kits. | 08-19-2010 |
| 20100203647 | Chemical Reporters of Protein Acylation - Methods and kits for detecting acylated proteins produced by cells that have been cultured or by cells within an organism are provided. Also provided are methods and kits for detecting acylated proteins produced by cells where affinity purification tags are that facilitate detection are used. Compounds useful for the detection of acylated proteins are also provided. | 08-12-2010 |
| 20100189714 | POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS - The invention provides a polypeptide containing at least one IgG Fc region, wherein said at least one IgG Fc region is glycosylated with at least one galactose moiety connected to a respective terminal sialic acid moiety by a α 2, 6 linkage, and wherein said polypeptide having a higher anti-inflammatory activity as compared to an unpurified antibody. | 07-29-2010 |
| 20100169997 | PROMOTION OF SOMATIC EMBRYOGENESIS IN PLANTS BY WUSCHEL GENE EXPRESSION - The present invention relates to methods for promoting somatic embryogenesis from a tissue or organ of a plant, by overexpressing a Wuschel gene in said tissue or organ. In one embodiment, such overexpression can be used as a silent selectable marker for transgenic plants. In another embodiment, such expression can be used to confer apomixis to a plant. In another embodiment, such overexpression can be used to create haploid plants, which can be used to produce dihaploid plants. | 07-01-2010 |
| 20100150913 | ORGANIC COMPOUNDS - The present invention relates to compounds and compositions useful for inhibiting and/or reducing platelet deposition, adhesion and/or aggregation. The present invention also relates to methods for screening compounds and compositions useful for inhibiting or reducing platelet deposition, adhesion and/or aggregation. The present invention further relates to methods for the treatment or prophylaxis of thrombotic disorders, including stroke, myocardial infarction, unstable angina, peripheral vascular disease, abrupt closure following angioplasty or stent placement and thrombosis as a result of vascular surgery. | 06-17-2010 |
| 20100143337 | COMPOSITIONS AND METHODS FOR CHARACTERIZING AND REGULATING OLFACTORY SENSATION - The present invention relates to the characterization of odorant receptors. In particular, the present invention relates to the OR7D4 proteins and nucleic acids encoding OR7D4 proteins and cell systems for screening for modulators of OR7D4 receptors. The present invention further provides assays for the detection of OR7D4 polymorphisms and mutations associated with altered olfactory sensation states, as well as methods of screening for therapeutic agents, ligands, and modulators of OR7D4 receptors. | 06-10-2010 |
| 20100121407 | NEUROMODULATION HAVING NON-LINEAR DYNAMICS - Methods of neuromodulation in a live mammalian subject, such as a human patient. The method comprises applying electromagnetic energy to a target site in the nervous system of the subject using a signal comprising a series of pulses, wherein the inter-pulse intervals are varied using the output of a deterministic, non-linear, dynamical system comprising one or more system control parameters. In certain embodiments, the target site may be a site in the brain involved in generalized CNS (central nervous system) arousal. The dynamical system may be capable of exhibiting chaotic behavior. Also provided are apparatuses for neuromodulation and software for operating such apparatuses. | 05-13-2010 |
| 20100080799 | WSTF REGULATES THE DNA DAMAGE RESPONSE OF H2A.X VIA NOVEL TYROSINE KINASE ACTIVITY - The present invention relates to methods of detecting and regulating cellular DNA damage as well as methods of screening compounds suitable for modulating cellular DNA damage. The methods of the present invention utilize antibodies that selectively bind to a phosphorylated tyrosine residue in a SQEY tyrosine phosphorylation motif sequence or a phosphorylated serine residue in a KENSSQ phosphorylation motif sequence, where the phosphorylated serine residue is closest to the glutamine residue. Also encompassed by the present invention are methods of treating a subject having cancer. These methods involve the administration of an agent that modulates the phosphorylation of the tyrosine residue in a SQEY motif. Suitable agents for modulating the phosphorylation of the tyrosine residue of the SQEY motif are also disclosed. | 04-01-2010 |
| 20100062419 | Infectious, Chimeric Hepatitis C Virus, Methods of Producing the Same and Methods of Use Thereof - The present invention provides infectious recombinant Hepatitis C Viruses (HCV), and vectors, cells and animals comprising the same. The present invention provides methods of producing infectious recombinant HCV, and their use in identifying anti-HCV therapeutic agents, as well as sequences of HCV associated with HCV pathogenesis. | 03-11-2010 |
| 20100003720 | ENZYME DERIVED FROM THERMOPHILIC ORGANISMS THAT FUNCTIONS AS A CHROMOSOMAL REPLICASE, AND PREPARATION AND USES THEREOF - A DNA Polymerase has been identified in a thermophile that functions as a chromosomal replicase. The specific enzyme is a holoenzyme III that has been identified in | 01-07-2010 |
| 20090298857 | Treatment of Neurodegenerative Diseases Through Inhibition of HSP90 - Treatment of neurodegenerative diseases is achieved using small molecule purine scaffold compounds that inhibit Hsp90 and that possess the ability to cross the blood-brain barrier or are other wise delivered to the brain. | 12-03-2009 |
| 20090275729 | MICRORNA AND METHODS FOR INHIBITING SAME - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 11-05-2009 |
| 20090263378 | METHODS OF IDENTIFYING ANTI-INFLAMMATORY COMPOUNDS - A mammalian C-type lectin receptor type is identified which is shown to bind IgG antibodies or Fc fragments, thus inducing IVIG-related reversal of inflammation associated with various immune disorders. The identification of a DC-SIGN receptor type which interacts with IgG to promote a biological response reducing inflammation associated with immune disorders provides for methods of screening and selecting compounds which may be useful in treating various immune disorders by acting to modulate a DC-SIGN | 10-22-2009 |
| 20090244667 | HOLOGRAPHIC MICROSCOPE - The preferred embodiments of the present invention include a holography attachment device that is attachable to a digital imaging device to form a holographic microscope. The holography attachment device includes a chamber having at least one attachment mechanism to facilitate attachment of the chamber to a digital imaging device. The holography attachment device also includes a light source and a sample holder section, which is located between a proximate end and the distal end of the chamber. The light source is configured to radiate light within the chamber. The light passes through the sample holder section and impinges on an imaging sensor of a digital imaging device when the chamber is attached to the digital imaging device. The digital imaging device is capable of recording hologram information related to a sample held by the sample holder in the sample holder section. | 10-01-2009 |
| 20090233266 | STRUCTURE OF THE HEPATITIS C VIRUS NS2 PROTEIN - The present invention provides a crystallized C-terminal domain of an NS2 protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the C-terminal domain of hepatitis C virus NS2 protein, and methods of inhibiting hepatitis C virus infection, replication and/or pathogenesis, by interacting with the same. | 09-17-2009 |
| 20090170067 | Simian tropic, recombinant human immunodeficiency-1 viruses - The present invention relates to a vector for producing recombinant human immunodeficiency virus 1 (HIV-1) that is capable of infecting simian cells and monkeys. The recombinant HIV-1 overcomes blocks to infection mediated by simian cell gene products. Such recombinant viruses are useful for evaluating the effectiveness of antiretroviral therapies and vaccines. | 07-02-2009 |
| 20090142271 | DENDRITIC CELLS - The present invention provides systems for isolating, characterizing, and modulating brain dendritic cells. The invention may allow a better understanding of and opportunities to modulate neurodevelopmental processes (such as, for example, neurogenesis) and neurological diseases (such as, for example, Alzheimer's Disease). | 06-04-2009 |
| 20090117089 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS - This invention relates to immunogenic compounds which may serve as ligands for NKT (natural killer T) cells and to methods of use thereof in modulating immune responses. | 05-07-2009 |
| 20090111177 | Maintenance of Embryonic Stem Cells by the GSK-3 Inhibitor 6-Bromoindirubin-3'-Oxime - The present invention relates to methods for maintaining the undifferentiated state of embryonic stem cells without the use of a feeder layer by activating the Wnt signal transduction pathway or by inhibiting glycogen synthase kinase-3 activity by contacting the cell with, inter alia, 6-bromoindirubin-3′-oxime. The present invention also relates to embryonic stem cell lines and cells derived therefrom that have been isolated and cultured in the absence of a feeder layer. | 04-30-2009 |
| 20090098123 | HCV CORECEPTOR AND METHODS OF USE THEREOF - The invention relates to the discovery that the Claudin-1 protein functions as a co-receptor for entry of HCV into cells. Methods of inhibiting, preventing or mitigating HCV infections by inhibiting HCV interactions with Claudin-1 are provided. Methods of identifying agents or compounds that interfere with HCV interactions with Claudin-1 are also provided. Finally, useful kits, cell culture compositions, agents, and compounds related to the inhibition of HCV interactions with Claudin-1 are also disclosed. | 04-16-2009 |
| 20090075394 | Voltage Sensor Domains of Voltage-Dependent Ion Channel Proteins and Uses Thereof - A composition of matter suitable for use in identifying chemical compounds that bind to voltage-dependent ion channel proteins, the composition comprising a screening protein that comprises an ion channel voltage sensor domain of the ion channel protein immobilized on a solid support. | 03-19-2009 |
| 20090060911 | ENHANCEMENT OF ANTIBODY-MEDIATED IMMUNE RESPONSES - The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to FcγRIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting FcγRIIB molecule is a potent regulator of cytotoxicity in vivo. | 03-05-2009 |
| 20090043082 | MICRORNA AND METHODS FOR INHIBITING SAME - The invention relates to isolated DNA or RNA molecules comprising at least ten contiguous bases having a sequence in a pancreatic islet microRNA. In another embodiment, the invention relates to isolated single stranded pancreatic islet microRNA molecules or anti-pancreatic islet microRNA molecules. | 02-12-2009 |
| 20090017029 | Methods and Compositions for Treating Ocular Disorders - The present invention relates to identification of a human gene, Complement Factor H (CFH), associated with the occurrence for developing age related macular degeneration (AMD), which is useful for identifying or aiding in identifying individuals at risk for developing AMD, as well as for diagnosing or aiding in the diagnosis or AMD. | 01-15-2009 |
| 20090004675 | Method of Identifying Compounds for Bacterial Growth Modulation - The present invention relates to a method of identifying a candidate compound for modulating bacterial growth. This the method involves providing a β clamp peptide from a bacterial replicase, providing a second peptide that binds to at least one amino acid of SEQ ID NO:9 that is not designated X, wherein the second peptide does not exhibit polymerase activity, and providing a test compound. The β clamp peptide and the second peptide are contacted with the test compound, and the level of binding between the β clamp peptide and the second peptide in the presence of the test compound is determined. The level of binding between the β clamp peptide and the second peptide in the presence of the test compound is then compared to a control that does not contain the test compound. A test compound that alters the level of binding between the β clamp peptide and the second peptide compared to the control is a candidate compound for modulating bacterial growth. | 01-01-2009 |
| 20090004179 | POLYPEPTIDES WITH ENHANCED ANTI-INFLAMMATORY AND DECREASED CYTOTOXIC PROPERTIES AND RELATING METHODS - The invention provides methods of altering properties of Fc-containing molecule, comprising altering the sialylation of the oligosaccharides in the Fc region. Proteins having Fc regions having altered sialylation patterns are also provided. | 01-01-2009 |
| 20090004111 | Structure of the Hepatitis C Ns5a Protein - The present invention provides a crystallized N-terminal domain of an NS5A protein of hepatitis C virus, methods of producing the same and methods of use thereof. The present invention also relates to structural elements of the N-terminal domain of hepatitis C virus NS5A protein, and methods of inhibiting hepatitis C virus infection, replication and/or pathogenesis, by interacting with the same. | 01-01-2009 |
| 20080313773 | PRODUCTION OF ARTIFICIAL MICRORNAS USING SYNTHETIC MICRORNA PRECURSORS - The invention provides methods and compositions useful in target sequence suppression, target sequence validation and target sequence down regulation. The invention provides polynucleotide constructs useful for producing artificial microRNA (amiRNA) using synthetic amiRNA precursors. | 12-18-2008 |
